photochemically inactivated Epstein-Barr virus-infected B-cell vaccine

The photochemically inactivated Epstein-Barr virus (EBV)-infected B-cell vaccine is an investigational autologous or allogeneic cell-based immunotherapy designed to treat EBV-associated malignancies. The vaccine consists of B-lymphoblastoid cell lines (LCLs) generated by infecting a patient's or donor's B cells with EBV in vitro. These cells express a broad range of EBV-encoded latent proteins (Latency III program), including EBNA and LMP proteins. To ensure safety, the cells are photochemically inactivated using a psoralen compound, typically amotosalen (S-59), combined with ultraviolet A (UVA) light. This process creates irreversible cross-links in the cellular and viral DNA, preventing replication and proliferation while preserving the structural integrity and immunogenicity of the cell-surface antigens and costimulatory molecules (such as CD80 and CD86). Upon administration, these inactivated LCLs function as potent antigen-presenting cells that stimulate and expand EBV-specific cytotoxic T-lymphocytes (CTLs), which can then identify and destroy EBV-positive tumor cells.

Other names

photochemically inactivated EBV-LCL vaccineS-59 inactivated EBV-infected B-cell vaccineS59 inactivated EBV-infected B-cell vaccineS 59 inactivated EBV-infected B-cell vaccineinactivated Epstein-Barr virus-infected B-cell vaccine